Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase
Research output: Contribution to journal › Journal article › Research › peer-review
Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) are promising cancer drugs currently in clinical trials in oncology, including APO866, CHS-828 and the CHS-828 prodrug EB1627/GMX1777, but cancer cell resistance to these drugs has not been studied in detail.
|Number of pages||13|
|Publication status||Published - 10 Dec 2010|
- Faculty of Health and Medical Sciences